Genprex (GNPX) News Today $0.70 -0.02 (-3.44%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.69%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes ProgramsJanuary 15, 2025 | americanbankingnews.comGenprex to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comGenprex receives Safety Review Committee approval to advance Acclaim-3 trialDecember 17, 2024 | markets.businessinsider.comGenprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerDecember 16, 2024 | prnewswire.comGenprex signs exclusive license agreement with University of MichiganNovember 20, 2024 | markets.businessinsider.comGenprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerNovember 20, 2024 | prnewswire.comGenprex to present positive preclinical data from Reqorsa Gene Therapy studyNovember 6, 2024 | markets.businessinsider.comGenprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNovember 5, 2024 | prnewswire.comGenprex to Participate in 2024 BIO Europe ConferenceOctober 31, 2024 | prnewswire.comLooking Into Genprex's Recent Short InterestOctober 30, 2024 | benzinga.comGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and GlioblastomaOctober 28, 2024 | prnewswire.comGenprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK PositiveOctober 24, 2024 | prnewswire.comGenprex (NASDAQ:GNPX) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comGenprex advances dose in lung cancer trialOctober 17, 2024 | investing.comGenprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerOctober 15, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 10, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingOctober 7, 2024 | prnewswire.comGenprex, Inc. (GNPX) interactive stock chart – Yahoo FinanceSeptember 25, 2024 | au.finance.yahoo.comGenprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesSeptember 23, 2024 | prnewswire.comGenprex Announces Formation of Mesothelioma Clinical Advisory BoardSeptember 19, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsSeptember 9, 2024 | prnewswire.comGenprex Plans To Launch New Subsidiary To Focus Gene Therapy To Treat Type-1, Type-2 DiabetesSeptember 4, 2024 | markets.businessinsider.comGenprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesSeptember 4, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 3, 2024 | prnewswire.comGenprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical TrialsAugust 15, 2024 | prnewswire.comGenprex stock slides 14% following Reqorsa study updatesAugust 15, 2024 | msn.comGenprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung CancerAugust 14, 2024 | prnewswire.comGenprex, Inc.: Genprex Granted Patent in Singapore for Reqorsa Gene Therapy with PD-1 Antibodies to Treat CancersAugust 14, 2024 | finanznachrichten.deNasdaq Surges 200 Points; US Producer Prices Increase 0.1% In JulyAugust 13, 2024 | msn.comS&P 500 Gains 1%; Home Depot Earnings Top ViewsAugust 13, 2024 | benzinga.comGenprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat CancersAugust 13, 2024 | prnewswire.comGNPX Stock Earnings: Genprex Reported Results for Q2 2024August 12, 2024 | investorplace.comGenprex to Present at the August Sidoti Microcap ConferenceAugust 8, 2024 | prnewswire.comGenprex Issues Stockholder Letter and Provides 2024 Corporate UpdateJune 27, 2024 | prnewswire.comGenprex to Present at the 2024 BIO International ConventionMay 30, 2024 | prnewswire.comGNPX Stock Earnings: Genprex Beats EPS for Q1 2024May 20, 2024 | msn.comGenprex’s Promising Clinical Trials and Leadership Drive Buy RatingMay 15, 2024 | markets.businessinsider.comGenprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerMay 14, 2024 | prnewswire.comGenprex Appoints Toscano As ChairmanMay 13, 2024 | markets.businessinsider.comGenprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsMay 13, 2024 | prnewswire.comGenprex, Inc.: Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 9, 2024 | finanznachrichten.deGenprex Co-Founder, CEO Rodney Varner Dies of CancerMay 8, 2024 | marketwatch.comGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerMay 8, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming May Investor and Industry ConferencesMay 1, 2024 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | finance.yahoo.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingApril 9, 2024 | prnewswire.comGenprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock UpApril 3, 2024 | markets.businessinsider.comGenprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerApril 3, 2024 | prnewswire.comGenprex: Collaborators Report Positive Preclinical Data With NPRL2 Gene TherapyApril 2, 2024 | markets.businessinsider.comGenprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemApril 2, 2024 | prnewswire.com Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address GNPX Media Mentions By Week GNPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼0.000.57▲Average Medical News Sentiment GNPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼11▲GNPX Articles Average Week Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ENLV News Today BCAB News Today LPCN News Today PLUR News Today EQ News Today FBRX News Today CYTH News Today PULM News Today NXTC News Today MRKR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
